Clinical Trials in Red Deer, Alberta
21 recruiting
Showing 1–20 of 21 trials
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Hoffmann-La Roche160 enrolled73 locationsNCT06863961
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
Migraine
Pfizer200 enrolled48 locationsNCT06616194
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Menstrual Migraine
Pfizer723 enrolled122 locationsNCT06641466
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1152 locationsNCT07064473
Recruiting
Phase 2
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
Hidradenitis Suppurativa
Pfizer240 enrolled54 locationsNCT07228390
Recruiting
Phase 1Phase 2
Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
Healthy VolunteersVasomotor Symptoms Associated With Menopause
AbCellera Biologics Inc.136 enrolled13 locationsNCT07118891
Recruiting
Not Applicable
Implementing REmote SymPtom mOnitoring and maNagement (RESPONd)
Cancer
University of Calgary1,055 enrolled4 locationsNCT07024329
Recruiting
Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Clostridium Difficile Infection RecurrenceClostridium DifficileClostridioides Difficile Infection+7 more
Vedanta Biosciences, Inc.852 enrolled215 locationsNCT06237452
Recruiting
Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Cardiovascular Disease
AstraZeneca15,100 enrolled1264 locationsNCT07000357
Recruiting
Phase 3
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Atopic Dermatitis
Organon and Co180 enrolled48 locationsNCT07265479
Recruiting
Phase 2
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Chronic Spontaneous Urticaria
Pfizer200 enrolled52 locationsNCT07219615
Recruiting
Phase 3
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Severe Alopecia Areata
Pfizer225 enrolled80 locationsNCT07029711
Recruiting
Dialyzing Wisely - Improving the Delivery of Acute Renal Replacement Therapy to Albertans
Acute Renal Injury
University of Alberta4,500 enrolled15 locationsNCT05186636
Recruiting
Phase 3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Hidradenitis Suppurativa
AbbVie1,328 enrolled285 locationsNCT05889182
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Alopecia Areata
Sun Pharmaceutical Industries, Inc.355 enrolled64 locationsNCT07133308
Recruiting
Not Applicable
Evaluation of Effectiveness of Child-oriented Goal-setting in Paediatric Rehabilitation (the ENGAGE Approach)
Cerebral PalsyAutism Spectrum DisorderNeurodevelopmental Disorders
University of Alberta96 enrolled6 locationsNCT04096430
Recruiting
Phase 3
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Alopecia Areata
Pfizer550 enrolled114 locationsNCT06873945
Recruiting
Phase 3
ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Stroke, AcuteAcute Ischemic Stroke AISStroke, Acute, Stroke Ischemic
University of Calgary4,000 enrolled24 locationsNCT06320431
Recruiting
Phase 3
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Vitiligo
Pfizer400 enrolled74 locationsNCT06163326
Recruiting
Not Applicable
Alberta Collaborative QI Strategies to Improve Outcomes of Moderate and Late Preterm Infants (ABC-QI Trial)
Length of Stay
University of Calgary9,500 enrolled12 locationsNCT05231200